Invest in AI-Powered Medical Diagnostics: US Capital Global Securities Announces $25M Offering for Scanbo Technologies, Inc.
Explore a unique investment opportunity in Scanbo Technologies, a MedTech and AI diagnostics company delivering rapid, ultra-portable point-of-care testing powered by artificial intelligence.
SAN FRANCISCO, JANUARY 2026 – US Capital Global Securities LLC, an SEC-registered affiliate of the global financial group US Capital Global, is pleased to present eligible investors with the opportunity to participate in a $25 million equity offering for Scanbo Technologies, Inc. (“Scanbo” or the “Company”), a MedTech and AI diagnostics firm redefining point-of-care testing.
Scanbo delivers fast, accurate, and affordable diagnostic results through a single, ultra-portable device powered by proprietary AI. The platform provides vital health insights in under five minutes, supporting faster clinical decisions, reducing diagnostic costs, and expanding access to primary care—particularly in underserved and resource-limited settings.
“We’re addressing a clear and urgent need in healthcare: fast, reliable diagnostics at the point of care,” said Ashissh Raichura, Founder and CEO of Scanbo. “Our platform delivers results in minutes, reduces costs, and expands access—especially in underserved regions. Our scalable device ecosystem and AI capabilities open new pathways for better outcomes and long-term growth.”
“Scanbo has developed and commercialized a robust diagnostic platform already gaining traction across global markets,” said Lisa Terk, Senior Vice President at US Capital Global. “With growing device deployments, expanding test capabilities, and a strong international pipeline, the Company is poised to scale its footprint significantly. We are delighted to support Scanbo’s $25 million equity raise and invite eligible investors to review this opportunity.”
About Scanbo Technologies, Inc.
Established in 2019, Scanbo develops integrated diagnostic solutions that streamline clinical decision-making and reduce reliance on traditional lab infrastructure. Its platform combines sensor-based testing, AI analysis, and secure digital connectivity to support timely triage, chronic condition monitoring, and seamless data sharing—empowering healthcare providers to deliver more efficient, data-informed care across diverse settings. Learn more at www.scanbo.com.
About US Capital Global
US Capital Global Securities LLC (“USCGS”) serves as the FINRA-member broker-dealer division of US Capital Global, specializing in facilitating growth-stage investments. Since 1998, US Capital Global has been dedicated to providing lower middle market businesses and investors with sophisticated investment opportunities. For further details about US Capital Global Securities or this investment opportunity, contact Lisa Terk, Senior Vice President, at lterk@uscapital.com or call +1 415-889-1026.
Disclaimer: USCGS or its affiliates may provide advice to, be compensated by, have other business relationships with, or may from time to time acquire, hold, or sell a position in the securities of the issuers mentioned herein. Any offer or solicitation shall be made only pursuant to the confidential private placement memorandum. View USCGS’ Form CRS at www.uscapglobalsecurities.com/crs.html.
Download a PDF of this Press Release
Media Q&A / FAQs
What is this announcement about?
This press release announces that US Capital Global Securities LLC is presenting eligible investors with the opportunity to participate in a $25 million equity offering for Scanbo Technologies, Inc., a MedTech and AI diagnostics company focused on point-of-care testing.
What type of investment is being offered?
The announcement describes a $25 million equity offering for Scanbo Technologies, Inc., available to eligible investors.
What does Scanbo Technologies do?
Scanbo develops an ultra-portable diagnostic platform powered by proprietary AI designed to deliver fast diagnostic results and health insights at the point of care.
How quickly does the platform provide results?
The press release states that the platform can provide vital health insights in under five minutes.
What problem is Scanbo aiming to address?
The announcement highlights the need for fast, reliable diagnostics at the point of care, including expanding access to primary care in underserved and resource-limited settings and reducing diagnostic costs.
When was Scanbo established?
The press release states that Scanbo Technologies, Inc. was established in 2019.
What capabilities does the Scanbo platform combine?
The press release states the platform combines sensor-based testing, AI analysis, and secure digital connectivity to support timely triage, chronic condition monitoring, and data sharing.
How can eligible investors review this opportunity?
The press release includes a link inviting eligible investors to review the opportunity via DocSend.
Who is the contact for more information?
The press release lists Lisa Terk (Senior Vice President) as a contact for details about US Capital Global Securities or the investment opportunity, including email and phone contact information.
Are there any important offer/disclosure notes?
Yes. The press release states that any offer or solicitation is made only pursuant to a confidential private placement memorandum and includes disclosures regarding US Capital Global Securities and its affiliates.